What is the 13F Pro Quality Score for CTNM?

13F Pro ranks Contineum Therapeutics, Inc. (CTNM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CTNM's current score at https://13fpro.ai/research/CTNM (free sign-up required for the full ranking).

Where does 13F Pro source CTNM data?

All Contineum Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Contineum Therapeutics, Inc. files with the SEC under CIK 1855175. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CTNM in?

Contineum Therapeutics, Inc. (CTNM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CTNM research updated on 13F Pro?

CTNM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Contineum Therapeutics, Inc.(CTNM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1855175 CTNM stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CTNM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Contineum Therapeutics, Inc. (CTNM), a Healthcare sector company. CTNM is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Contineum Therapeutics, Inc. reports net income of $-14.5M, free cash flow of $-16.6M. Top institutional holders of CTNM by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT,, JANUS HENDERSON GROUP PLC, JOHNSON & JOHNSON, based on the most recent SEC filings. CTNM trades on the Nasdaq exchange and files with the SEC under CIK 1855175. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTNM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Contineum Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-14.5M

Free Cash Flow

Q1 2026

$-16.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY23 $50.0MFY24 $0.00FY25 —

Net Income

-41.9% YoY

$-60.0MFY 2025

FY23 $22.7MFY24 $-42.3MFY25 $-60.0M

Operating Income

-33.7% YoY

$-68.1MFY 2025

FY23 $16.1MFY24 $-50.9MFY25 $-68.1M

EPS (Diluted)

+0.5% YoY

$-2.17FY 2025

FY23 $0.08FY24 $-2.18FY25 $-2.17

Total Assets

+30.0% YoY

$276.6MFY 2025

FY23 $130.4MFY24 $212.8MFY25 $276.6M

Op. Cash Flow

-68.4% YoY

$-55.3MFY 2025

FY23 $19.3MFY24 $-32.8MFY25 $-55.3M

Metric	FY 2025	FY 2024	FY 2023
Revenue	—	$0.00 -100.0%	$50.0M
Net Income	$-60.0M -41.9%	$-42.3M -286.0%	$22.7M
Operating Income	$-68.1M -33.7%	$-50.9M -416.6%	$16.1M
EPS (Diluted)	$-2.17 +0.5%	$-2.18 -2825.0%	$0.08
Total Assets	$276.6M +30.0%	$212.8M +63.2%	$130.4M
Operating Cash Flow	$-55.3M -68.4%	$-32.8M -269.8%	$19.3M

AI Insight: CTNM Financial Trends

Contineum burns through $14-16M quarterly with no revenue, while equity volatility suggests irregular funding events.

• Operating losses stabilized around $15-18M quarterly from Q1 2025 onward after worsening from $11M in Q2 2024.

• Operating cash flow deteriorated from $-6M in Q3 2024 to $-16M in Q1 2026.

• Equity jumped from $171M in Q2 2025 to $261M in Q4 2025, indicating capital raise.

⚠ Zero revenue across all periods with consistent quarterly burn rate pressures cash runway.

⚠ Equity declined $11M in Q1 2026 after Q4 2025 capital injection, resuming burn trend.

AI Insight: CTNM Ratio Trends

Return on invested capital improved from -41.8% in Q2 2025 to -27.0% in Q1 2026, though remains deeply negative.

• ROIC recovered from -41.8% in Q2 2025 to -27.0% in Q1 2026, a 14.8pp improvement over three quarters.

• ROE similarly improved from -37.4% in Q2 2025 to -23.1% in Q1 2026, showing consistent profitability recovery.

• All profitability metrics remain deeply negative despite recent improvement, reflecting ongoing operational losses.

⚠ Recovery trend may stall as Q1 2026 ROIC of -27.0% shows minimal improvement from Q4 2025's -26.2%.

⚠ Missing operating margin and debt metrics limit visibility into operational efficiency and financial leverage trends.

Get alerted when CTNM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Contineum Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CTNM

SUVRETTA CAPITAL MANAGEMENT, LLC
$37.1M2,841,334 sh
JANUS HENDERSON GROUP PLC
$35.6M2,734,836 sh
JOHNSON & JOHNSON
$25.8M1,979,173 sh
FRANKLIN RESOURCES INC
$24.0M1,839,227 sh
BALYASNY ASSET MANAGEMENT L.P.
$22.0M1,685,635 sh
MILLENNIUM MANAGEMENT LLC
$20.1M1,535,449 sh
BAKER BROS. ADVISORS LP
$18.6M1,420,838 sh
RA CAPITAL MANAGEMENT, L.P.
$16.9M1,296,012 sh
PERCEPTIVE ADVISORS LLC
$16.4M1,255,592 sh
VANGUARD CAPITAL MANAGEMENT LLC
$15.9M1,214,173 sh

Fund	Value	Shares
SUVRETTA CAPITAL MANAGEMENT, LLC	$37.1M	2,841,334
JANUS HENDERSON GROUP PLC	$35.6M	2,734,836
JOHNSON & JOHNSON	$25.8M	1,979,173
FRANKLIN RESOURCES INC	$24.0M	1,839,227
BALYASNY ASSET MANAGEMENT L.P.	$22.0M	1,685,635
MILLENNIUM MANAGEMENT LLC	$20.1M	1,535,449
BAKER BROS. ADVISORS LP	$18.6M	1,420,838
RA CAPITAL MANAGEMENT, L.P.	$16.9M	1,296,012
PERCEPTIVE ADVISORS LLC	$16.4M	1,255,592
VANGUARD CAPITAL MANAGEMENT LLC	$15.9M	1,214,173

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CTNM on your watchlist

Track score changes the day Contineum Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CTNM a good stock to buy?

13F Pro's AI-powered analysis of Contineum Therapeutics, Inc. (CTNM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CTNM are available on the CTNM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CTNM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CTNM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Contineum Therapeutics, Inc.'s investment landscape.